热毒宁佐治儿童支原体肺炎的疗效及对IFN-γ、TNF-ɑ、IL-6的影响

doi:10.19739/j.cnki.issn1001-9510.2021.01.011

Abstract
Figure/Table
References
Related Citation (2)

Download: PDF (949 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical efficacy of reduning Injection in the treatment of mycoplasma pneumonia (MPP) in children and the level of IFN-γ, TNF-α and IL-6 in serum.Methods One hundred and twenty children with Mycoplasma pneumoniae pneumonia hospitalized in the second ward of Pediatrics, Yidu Central Hospital of Weifang from January 2018 to December 2019 were selected as the research objects. They were randomly divided into the control group (odd numbers as the control group) with 56 cases and the reduning group with 64 cases (even numbers as the reduning group). The control group was given conventional treatment; the reduning group was additionally given reduning 0.5ml/kg.d intravenous drip besides conventional treatment, with the maximum amount of 20 ml daily for 1 week. The clinical manifestations, therapeutic effects and serum inflammatory factors such as IL-6, TNF - α, IFN-γ before and after treatment were compared between the two groups. Results The two groups were cured after active treatment, but the length of hospital stay was different. The results showed that the fever subsided time, cough disappearance time, rales disappearance time and hospitalization days in reduning group were lower than those in the control group (P<0.05); the effective rate of reduning group was significantly better than that of control group; after 1 week of treatment, the level of IL-6 in reduning group was significantly lower than that in the control group (P<0.05). After 2 weeks of treatment, the levels of IL-6, TNF - α and IFN-γ in reduning group were significantly lower than those in the control group (P<0.05). There were few adverse reactions in the two groups.Conclusion Reduning can effectively improve the clinical manifestations of MPP, inhibit the expression of IL-6, TNF - α, IFN-γ and other inflammatory factors, so as to improve the effective rate of MPP treatment. Reduning is safe, efficient and has less adverse reactions, which is worthy of clinical promotion.

Key words： reduning injection mycoplasma pneumonia interferon-γ tumor necrosis factor-α interleukin-6

Received: 19 August 2020

PACS:

R725.6

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Yongfa
	LIN Cui
	ZHANG Haijun

Cite this article:

ZHANG Yongfa,LIN Cui,ZHANG Haijun. Effect of reduning injection on mycoplasma pneumonia in children and on IFN-γ, TNF - α and IL-6[J]. 滨州医学院学报, 2021, 44(1): 53-56.

URL:

http://manu58.magtech.com.cn/Jwk_bzyxy/EN/10.19739/j.cnki.issn1001-9510.2021.01.011 OR http://manu58.magtech.com.cn/Jwk_bzyxy/EN/Y2021/V44/I1/53

[1] 彭懿,舒畅,符州,等.儿童社区获得性肺炎1613例病原学特点分析[J].中国当代儿科,2015,17(11):1193-1199.
[2] 殷勇,陆权,闫晓莉,等.肺炎支原体感染的流行病学[J].中华儿科杂志,2016,54( 2 ): 91-93.
[3] 付晓燕,秦选光,辛德莉.小儿肺炎支原体感染耐药情况回顾分析[J].中国儿童保健杂志,2017,25(9):951-954.
[4] 朱燕文,蒋吴君,王宇清.儿童难治性肺炎支原体肺炎混合感染的临床特点分析[J].吉林医学,2019,40(1):29-31.
[5] 陈正荣,严永东.小儿肺炎支原体感染流行病学特征[J].中国实用儿科杂志,2015,30(3):180-183.
[6] 余丽丽,赵德育.肺炎支原体肺炎发病机制研究进展[J].中国实用儿科,2017,32(3): 234-238.
[7] 胡亚美.诸福棠实用儿科学[M].7版.北京:人民卫生出版社,2008:1204.
[8] 张晗,尚云晓.重症肺炎支原体肺炎早期识别[J].中国实用儿科杂志,2015,30(3):176-179.
[9] 李毅.儿科疾病诊断标准[M].北京:科学出版社,2001:167.
[10] 孙雷,于海彤,宫静,等.肺炎支原体感染的临床研究[J].世界最新医学信息文摘,2018,18(22):34-34.
[11] 孙越.热毒宁佐治儿童支原体肺炎疗效观察[J].临床荟萃,2014,29(5):580-581.
[12] 陆惠兰.热毒宁联合阿奇霉素治疗小儿支原体肺炎疗效观察[J].现代预防医学,2008,35(15):3007-3007.
[13] 李菁,包军,鲍一笑,等.肺炎支原体肺炎患儿肺泡灌洗液病菌量及其与 Th1/Th2细胞免疫应答的关系[J].临床儿科杂志,2015,33(8):681-685.
[14] 郭伟,张同强,徐勇胜,等.肺炎支原体肺炎患儿 TNF-α、IFN-γ和 IL-4 细胞因子水平的变化[J].中国现代医学杂志,2018,28(23): 65-68.
[15] 杨丽娟,许美善,曹丽芳,等.小儿难治性支原体肺炎血清 TNF-α、IL-4、IL-10 水平变化及临床意义[J].现代生物学进展,2017,17(8):1487-1489.
[16] 王国健,许卫东,李志武.热毒宁注射液联合甲强龙治疗小儿支原体肺炎的疗效及其对TNF-ɑ、IL-8、IL-6以及hs-CRP的影响[J].海南医学,2017,28(24):4088-4090.